Neuraxapharm Group, a European-based pharmaceutical company that focuses on central nervous system (CNS) announced last week that it had signed a binding agreement to divest API developer and manufacturer company, Inke, to private equity manager Keensight Capital.
/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS).
/PRNewswire/ Neuraxpharm Group (Neuraxpharm), a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS).
Neuraxpharm expands into the Netherlands The CNS specialist continues its strong expansion course in Europe and increases its presence from two to 20 countries in just six years Naarden and Düsseldorf – December 7, 2022 – Neuraxpharm Group (Neuraxpharm), a leading European specialty pharma.